NHAS
AVBP icon

Novo Holdings A/S’s ArriVent BioPharma AVBP Stock Holding History

Novo Holdings A/S’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.8M Hold
1,942,142
– – 3.63% 11
2025
Q4 		$39.1M Hold
1,942,142
– – 3.03% 14
2025
Q3 		$35.8M Buy
1,942,142
+70,000
+4% +$1.38M 2.31% 14
2025
Q2 		$40.8M Hold
1,872,142
– – 2.88% 11
2025
Q1 		$34.6M Buy
1,872,142
+351,515
+23% +$8.6M 2.63% 12
2024
Q4 		$40.5M Buy
1,520,627
+15,312
+1% +$440K 2.45% 13
2024
Q3 		$35.4M Buy
1,505,315
+5,315
+0.4% +$121K 1.76% 15
2024
Q2 		$27.8M Buy
1,500,000
+422,860
+39% +$7.54M 1.5% 22
2024
Q1 		$19.2M Buy
+1,077,140
New +$21.7M 1.33% 25

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Novo Holdings A/S's AVBP Position: Q1 2026 in Review

Novo Holdings A/S held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 1,942,142 shares worth $44.8M. The position accounts for 3.63% of the portfolio, ranked #11.

Novo Holdings A/S first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Novo Holdings A/S held 1,942,142 shares of ArriVent BioPharma worth $44.8M as of Q1 2026.
  • Novo Holdings A/S left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up 3.63% of Novo Holdings A/S's portfolio in Q1 2026, its #11 holding.
  • Novo Holdings A/S first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.